Ethics and the Pharmaceutical Industry
$46.99 (P)
- Authors:
- Michael A. Santoro, Rutgers University, New Jersey
- Thomas M. Gorrie
- Date Published: July 2007
- availability: Available
- format: Paperback
- isbn: 9780521708883
$
46.99
(P)
Paperback
Other available formats:
Hardback, eBook
Looking for an examination copy?
This title is not currently available for examination. However, if you are interested in the title for your course we can consider offering an examination copy. To register your interest please contact collegesales@cambridge.org providing details of the course you are teaching.
-
Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Debates are raging over how the industry can and should be expected to act. In this volume leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, marketing and advertising. . Michael Santoro is Associate Professor with tenure in the Business Environment Department at Rutgers Business School, where he teaches courses on business ethics, public policy, labor and human rights, law, ethical issues in the pharmaceutical industry and China business strategy. As a Research Associate at Harvard Business School, he wrote or co-authored nearly thirty case studies and teaching notes on ethical and legal topics such as global protection of intellectual property, insider trading, the Federal Sentencing Guidelines and Fair Credit Reporting Act. Thomas Gorrie is Corporate Vice President, Government Affairs & Policy, at Johnson & Johnson, with responsiblity for all federal, state and international government affairs and policy. He completed post-doctoral studies at the Swiss Federal Institute of Technology in Zurich, following the receipt of his doctorate at Princeton University. Gorrie has over 30 years of worldwide health care experience and has worked with various Johnson & Johnson companies in research and development, marketing and sales, business development, strategic planning, general management, international, venture capital, and health policy.
Read more- Extremely topical, accessible collection on drug pricing, safety, marketing, advertising, and patenting
- First book to bring together high-level representatives of industry, government, NGOs, leading thinkers in medicine, health ethics, and economics
- Authors propose solutions - safeguards, ethical guidelines and other recommendations - to the ethical problems of drug companies in society
Reviews & endorsements
"Santoro and Gorrieas book tackles one of the most controversial issues affecting our society 'healthcare: an economic commodity or basic human right?' At the heart of this debate is the role of the pharmaceutical industry. The book highlights effectively the opposing forces underlying the tension between the need for financial incentive for drug discovery and the global need for affordable medicines. It succeeds in providing provocative yet balanced perspectives from leaders of industry, government, ethics, business and healthcare. This book is a must read."
-Dr. Victor J. Dzau, President and Chief Executive Officer, Duke University Health System and Chancellor for Health Affairs, Duke University Medical CenterSee more reviews"For intelligent debate on the crisis of confidence in Big Pharma, this volume is unsurpassed. Santoro and Gorrie have assembled an impressive array of voices to tackle contentious issues plaguing the industry, from physician professionalism and research integrity to drug pricing, direct-to-consumer advertising, and intellectual property rights. Combining rigorous analysis with provocative proposals for change, this timely volume should be prescribed reading for industry leaders, policy-makers, and citizens alike."
-Lynn S. Paine, John G. McLean Professor of Business Administration, Harvard Business School"This book provides thoughtful dialogue from diverse viewpoints on some of the most significant issues in health care -- we need this kind of meaningful dialogue to happen more often."
-Tommy G. Thompson, Former Secretary of Health and Human Services and Former Governor of Wisconsin"Michael Santoro and Thomas Gorrie have compiled a series of essays that provide a fair, balanced, and insightful examination of an increasingly troubled relationship between the pharmaceutical industry and society."
-Henry Thomas Stelfox, Journal of the American Medical Association"Ethics and the Pharmaceutical Industry is a timely and thoughtful addition to the growing literature on this controversial subject...I highly recommend this collection of essays as a beginning of a pathway for all parties involved in healthcare."
-Alan T. Kaell, Pharmacy and Therapeutics"Suffice it to say the book has something in it for almost everyone interested in health care, ethics, and pharmaceuticals. You will learn something from some of the authors, while others will likely make you mad. But they all make you think."
-Merrill Matthews, Journal of the National Association for Business Economics"Santoro and Gorrie have woven together a rich collection of perspectives in Ethics and the Pharmaceutical Industry, with contributors ranging from activists and academicians to regulators and representatives from the industry."
-Jeremy Sugarman, Johns Hopkins University, The New England Journal of Medicine"Santoro, Gorrie and their contributors succeed in assembling a text that presents the key issues of business conduct for multinational pharmaceutical corporations, in a spirit of dialogue and respect for truly diverse perspectives."
-William Avery Hudson blog"A timely and fair-minded overview of many drug-related issues."
-Future SurveyCustomer reviews
Not yet reviewed
Be the first to review
Review was not posted due to profanity
×Product details
- Date Published: July 2007
- format: Paperback
- isbn: 9780521708883
- length: 528 pages
- dimensions: 229 x 152 x 30 mm
- weight: 0.68kg
- availability: Available
Table of Contents
Charting a sustainable path for the 21st century pharmaceutical industry Michael A. Santoro
Part I. Profits, Patients' Rights, and Scientific Progress: The Ethics of Clinical Research Conducted in Private Enterprises:
1. Drug research: between ethical demands and economic constraints Jurgen Drews
2. Emerging international norms for clinical testing: good clinical trial practice Juhana E. Idanpaan-Heikkila and Sev S. Fluss
3. The regulatory and ethical challenges of pediatric research M. Dianne Murphy and Sara F. Goldkind
4. Including children in research: participation or exploitation? Robert M. Nelson
5. Racial and ethnic inclusiveness in clinical trials Valentine J. Burroughs
6. The rights of patients to participate in clinical trials Glenna Crooks
7. How should government regulate stem-cell research? Perspectives of a scientist-legislator The Hon. Rush Holt
Part II. Marketing and the Efficient Utilization of Healthcare Resources: Ethical and Public Policy Challenges:
8. Ethics and prescribing: the clinician's perspective Charles L. Bardes
9. Direct-to-consumer advertising of prescription drugs: a policy dilemma Meredith B. Rosenthal and Julie M. Donohue
10. Regulation of prescription drug promotion Thomas Abrams
11. Off-label communications in marketing prescription drugs Scott D. Danzis
12. The need for better health information: advancing the informed patient in Europe Don E. Detmer, Peter Singleton and Scott C. Ratzan
13. Who should get access to which drugs? An ethical template for pharmacy benefits Norman Daniels, James E. Sabin and J. Russell Teagarden
14. The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals Joel Hay
Part III. Patents, Pricing, and Equal Access:
15. Intellectual property rights, access to life-enhancing drugs, and corporate moral responsibilities Patricia H. Werhane and Michael Gorman
16. A future agenda for government-industry relations William Weldon
17. AIDS activism and the pharmaceutical industry Martin Delaney
18. The campaign against innovation Sidney Taurel
19. Third world perspectives on global pharmaceutical access James Thuo Gathii
20. The promise of vaccines and the influenza shortage of 2004: public and private partnerships Gary R. Noble
Part IV. Charting a Sustainable Path for the 21st Century:
21. Evolving approaches to healthcare challenges Thomas M. Gorrie
22. Property rights in crisis: managers and rescue Nien-he Hsieh
23. Blurring the lines: public and private partnerships addressing global health William Foege
24. Renegotiating the grand bargain: balancing prices, profits, people, and principles Greg Koski.
Sorry, this resource is locked
Please register or sign in to request access. If you are having problems accessing these resources please email lecturers@cambridge.org
Register Sign in» Proceed
You are now leaving the Cambridge University Press website. Your eBook purchase and download will be completed by our partner www.ebooks.com. Please see the permission section of the www.ebooks.com catalogue page for details of the print & copy limits on our eBooks.
Continue ×Are you sure you want to delete your account?
This cannot be undone.
Thank you for your feedback which will help us improve our service.
If you requested a response, we will make sure to get back to you shortly.
×